ROXITHROMYCIN

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C41H76N2O15
Molecular Weight	837.0465
Optical Activity	UNSPECIFIED
Defined Stereocenters	18 / 18
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O

InChI

InChIKey=RXZBMPWDPOLZGW-XMRMVWPWSA-N

InChI=1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3/b42-31+/t22-,23-,24+,25+,26-,27+,28+,29-,30+,32-,33+,34-,35+,36-,38+,39-,40-,41-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C41H76N2O15
Molecular Weight	837.0465
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	18 / 18
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: http://www.nps.org.au/medicines/infections-and-infestations/antibiotics/for-individuals/antibiotics-for-respiratory-tract-infections/for-individuals/active-ingredients/roxithromycin/for-individuals/brands/roxithromycin-sandoz-tablets

Roxithromycin is a semi-synthetic macrolide antibiotic, which was developed by Roussel Uclaf and is available in Australia. Roxithromycin prevents bacteria from growing, by interfering with their protein synthesis. Roxithromycin binds to the subunit 50S of the bacterial ribosome, and thus inhibits the translocation of peptides. It can treat respiratory tract, urinary and soft tissue infections.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial 70S ribosome 180 Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15386112	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Acute pharyngitis 2 Sources: http://www.nps.org.au/medicines/infections-and-infestations/antibiotics/for-individuals/antibiotics-for-respiratory-tract-infections/for-individuals/active-ingredients/roxithromycin/for-individuals/brands/roxithromycin-sandoz-tablets	Curative	Not Provided 511	ROXITHROMYCIN SANDOZ Approved Use Unknown
Acute bronchitis 10 Sources: http://www.nps.org.au/medicines/infections-and-infestations/antibiotics/for-individuals/antibiotics-for-respiratory-tract-infections/for-individuals/active-ingredients/roxithromycin/for-individuals/brands/roxithromycin-sandoz-tablets	Curative	Not Provided 511	ROXITHROMYCIN SANDOZ Approved Use Unknown
Pneumonia 91 Sources: http://www.nps.org.au/medicines/infections-and-infestations/antibiotics/for-individuals/antibiotics-for-respiratory-tract-infections/for-individuals/active-ingredients/roxithromycin/for-individuals/brands/roxithromycin-sandoz-tablets	Curative	Not Provided 511	ROXITHROMYCIN SANDOZ Approved Use Unknown
Skin and soft tissue infections 33 Sources: http://www.nps.org.au/medicines/infections-and-infestations/antibiotics/for-individuals/antibiotics-for-respiratory-tract-infections/for-individuals/active-ingredients/roxithromycin/for-individuals/brands/roxithromycin-sandoz-tablets	Curative	Not Provided 511	ROXITHROMYCIN SANDOZ Approved Use Unknown
Non gonococcal urethritis 1 Sources: http://www.nps.org.au/medicines/infections-and-infestations/antibiotics/for-individuals/antibiotics-for-respiratory-tract-infections/for-individuals/active-ingredients/roxithromycin/for-individuals/brands/roxithromycin-sandoz-tablets	Curative	Not Provided 511	ROXITHROMYCIN SANDOZ Approved Use Unknown

PubMed

Title	Date	PubMed
Macrolides attenuate mucus hypersecretion in rat airways through inactivation of NF-kappaB.	2008-01	18197913
Inhibition of sulfur mustard-induced cytotoxicity and inflammation by the macrolide antibiotic roxithromycin in human respiratory epithelial cells.	2007-05-24	17524151
Mechanisms of venoocclusive disease resulting from the combination of cyclophosphamide and roxithromycin.	2006-12	17164692
Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.	2006-10	16837568
Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide dosing and roxithromycin.	2006-04	16595573
Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.	2006-03	16416302
Roxithromycin inhibits constitutive activation of nuclear factor {kappa}B by diminishing oxidative stress in a rat model of hepatocellular carcinoma.	2005-08-01	16061884
In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis.	2005-04	15793125
Acute renal failure and hepatotoxicity associated with roxithromycin.	2004-04	14766998
Effects of eight antibacterial agents on cell survival and expression of epithelial-cell- or cell-adhesion-related genes in human gingival epithelial cells.	2004-02	14687228
Reversible anosmia after amikacin therapy.	2003-12	14676161
Roxithromycin promotes lymphocyte apoptosis in Dermatophagoides-sensitive asthma patients.	2003-08-08	12921874
Roxithromycin induced torsade de pointes in a patient with complex congenital heart disease and complete atrioventricular block.	2003-06	12822762
HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions.	2002-10-17	12380704
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001-11	11792017
Possible roxithromycin-induced fulminant hepatic failure in a child.	2001-07	11444584
In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials.	2000-01	10602744
In-vitro activity of lytic peptides alone and in combination with macrolides and inhibitors of dihydrofolate reductase against Pneumocystis carinii.	1998-10	9818742
[Macrolide antibiotic-induced vasculitis (Churg-Strauss syndrome)].	1998-02	9555706
Immediate reaction to roxithromycin and prick test cross-sensitization to erythromycin and clarithromycin.	1998	9621142
In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis.	1997-12	9462443
Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.	1996-11	8913450
Roxithromycin-induced digoxin toxicity.	1996-10-21	8913245
In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum.	1996-09	8889715
Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice.	1996-04	8849223
International Congress on Chemotherapy.	1995-09	11362904
In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii.	1995-06	7559193
In vitro activity of roxithromycin against the Mycobacterium tuberculosis complex.	1995-05	7625806
Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages.	1995-04	7786006
Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice.	1995-04	7785988
In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi.	1994-10	7840584
Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex.	1994-06	8092850
In vitro activity of roxithromycin against 16 species of atypical mycobacteria and effect of pH on its radiometric MICs.	1993-07	8363393
In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii.	1991-06	1655433
[Activity of azithromycin and roxithromycin alone or in combination against Mycobacterium avium and Mycobacterium xenopi].	1990-05	2164181
In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.	1989-09	2817858
In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii.	1988-04	2837140
In vitro activity of antimicrobial agents against mycobacteria.	1988	3150951
Roxithromycin, a new macrolide antibiotic, in the treatment of infections in the lower respiratory tract: an overview.	1987-11	3323166
In vitro susceptibility of Mycobacterium tuberculosis to a new macrolide antibiotic: RU-28965.	1987-06	3116734
In vivo synergism of roxithromycin (RU 965) and interferon against Toxoplasma gondii.	1987-02	3105452

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage for adults is 300mg per day. You may take this according to one of the following dosage regimens: one 300mg tablet once a day, or one 150mg tablet twice a day, or two 150 mg tablets once a day.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:56:29 GMT 2025` Edited by `admin` on `Mon Mar 31 17:56:29 GMT 2025`
Record UNII	21KOF230FA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NSC-758443

Preferred Name

English

ROXITHROMYCIN

Official Name

English

RU 965

Code

English

ROXITHROMYCIN [MART.]

Common Name

English

RU-965

Code

English

(E)-ERYTHROMYCIN-9-(O-((2-METHOXYETHOXY)METHYL)OXIME)

Common Name

English

roxithromycin [INN]

Common Name

English

ERYTHROMYCIN 9-(E)-(O-((2-METHOXYETHOXY)METHYL)OXIME)

Common Name

English

ERYTHROMYCIN A, 9-(O-(2-METHOXYETHOXYMETHYL)-OXIME)

Common Name

English

ROXITHROMYCIN [JAN]

Common Name

English

ROXITHROMYCIN [MI]

Common Name

English

ROXITHROMYCIN [USAN]

Common Name

English

RU 28965

Code

English

ROXITHROMYCIN [EP IMPURITY]

Common Name

English

RU-28965

Code

English

Roxithromycin [WHO-DD]

Common Name

English

(3R,4S,5S,6R,7R,9R,11S,12R,13S,14R)-4-((2,6DIDEOXY-3-C-METHYL-3-O-METHYL-.ALPHA.-L-RIBO-HEXOPYRANOSYL)OXY)-14-ETHYL-7,12,13-TRIHYDROXY-10-((E)((2-METHOXYETHOXY)METHOXY)IMINO)-3,5,7,9,11,13HEXAMETHYL-6-((3,4,6-TRIDEOXY-3-(DIMETHYLAMINO)-.BETA.-D-XYLOHEXOP

Systematic Name

English

Erythromycin 9-[O-[(2-methoxyethoxy)methyl]oxime]

Common Name

English

ROXITHROMYCIN [EP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QJ01FA06